Search Results - "Beygi, Sara"

Incidence of traumatic spinal cord injury worldwide: a systematic review by Jazayeri, Seyed Behzad, Beygi, Sara, Shokraneh, Farhad, Hagen, Ellen Merete, Rahimi-Movaghar, Vafa

“…Purpose Traumatic spinal cord injuries (TSCI) are among the most devastating conditions in developed and developing countries, which can be prevented. The…”
Get full text

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study by Ghione, Paola, Palomba, M Lia, Ghesquieres, Hervé, Bobillo, Sabela, Patel, Anik R, Nahas, Myrna, Kanters, Steve, Deighton, Kevin, Hatswell, Anthony, Ma, Long, Limbrick-Oldfield, Eve H, Snider, Julia Thornton, Wade, Sally W, Riberio, Maria Teresa, Radford, John, Beygi, Sara, Gribben, John

“…The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular lymphoma (FL) patients on 3rd line of treatment (LoT) or higher, for whom…”
Get full text

Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era by Beygi, Sara, Sadashiv, Santhosh, Reilly, James B, Khan, Cyrus, Lister, John

“…Treatment of diffuse large B cell lymphoma (DLBCL) remains challenging in elderly population and systematic reviews are lacking in this area. Medline and…”
Get full text

Improved patient quality of life following intradural extramedullary spinal tumor resection by Viereck, Matthew J, Ghobrial, George M, Beygi, Sara, Harrop, James S

“…OBJECTIVE Resection significantly improves the clinical symptoms and functional outcomes of patients with intradural extramedullary tumors. However, patient…”
Get full text

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity by Shree, Tanaya, Shankar, Vishnu, Lohmeyer, Julian J K, Czerwinski, Debra K, Schroers-Martin, Joseph G, Rodriguez, Gladys M, Beygi, Sara, Kanegai, Alyssa M, Corbelli, Karen S, Gabriel, Etelka, Kurtz, David M, Khodadoust, Michael S, Gupta, Neel K, Maeda, Lauren S, Advani, Ranjana H, Alizadeh, Ash A, Levy, Ronald

“…To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients with lymphoma, we assessed blocking antibodies, total anti-spike IgG,…”
Get full text

S223: REAL‐WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA by Jacobson, Caron, Hemmer, Michael T., Hu, Zhen‐Huan, Frank, Matthew, Popplewell, Leslie, Ahmed, Nausheen, Lin, Yi, Best, Timothy, Beygi, Sara, Miao, Harry, Fu, Christine, Sun, Fang, Xu, Hairong, Pasquini, Marcelo

Get full text

P1107: ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA by Flinn, Ian W., Jacobson, Caron, Nastoupil, Loretta J., Morschhauser, Franck, Davies, Andrew J., Buske, Christian, Corradini, Paolo, Lopez‐Guillermo, Armando, Reshef, Ran, Parameswaran, Vinod, Sehgal, Alison, Tees, Michael, Lui, Christine, Xue, Wei, Beygi, Sara, Grechko, Nikolay, Bolsue, Pisita, Giovanetti, Alessandro, To, Christina, Nahas, Myrna

Get full text

The Foot That Broke Both Hips: A Case Report and Literature Review of Tumor-Induced Osteomalacia by Beygi, Sara, Sharma, Tarun S., Denio, Alfred E.

“…Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia and clinical symptoms of osteomalacia. Only discussed as…”
Get full text

Does Ramadan Fasting Adversely Affect Cognitive Function in Young Females? by Ekhtiari, Hamed, Memari, Amir, Rahbar Nikoukar, Laya, Ghayour Najafabadi, Mahboubeh, Beygi, Sara

“…We examined the effects of Ramadan fasting on cognitive function in 17 female athletes. Data were obtained from participants of two fasting (n=9) and…”
Get full text

Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma by Beygi, Sara, Fernandez-Pol, Sebastian, Duran, George, Kim, Youn H., Khodadoust, Michael S.

“…Background: Mogamulizumab is a humanized anti-CCR4 antibody approved for the treatment of mycosis fungoides and Sézary Syndrome. Despite almost universal…”
Get full text

Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma by Beygi, Sara, Fernandez-Pol, Sebastian, Duran, George, Wang, Erica B, Kim, Youn, Khodadoust, Michael

Get full text

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma by Beygi, Sara, Duran, George E, Fernandez-Pol, Sebastian, Rook, Alain H, Kim, Youn H, Khodadoust, Michael S

“…Mogamulizumab is a humanized anti-CC chemokine receptor 4 (CCR4) antibody approved for the treatment of mycosis fungoides and Sézary syndrome. Despite almost…”
Get full text

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas by Sworder, Brian J., Kurtz, David M., Alig, Stefan K., Frank, Matthew J., Shukla, Navika, Garofalo, Andrea, Macaulay, Charles W., Shahrokh Esfahani, Mohammad, Olsen, Mari N., Hamilton, James, Hosoya, Hitomi, Hamilton, Mark, Spiegel, Jay Y., Baird, John H., Sugio, Takeshi, Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha D., Schroers-Martin, Joseph G., Liu, Chih Long, Oak, Jean S., Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason R., Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

“…Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize…”
Get full text

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) by Neelapu, Sattva S., Chavez, Julio C., Sehgal, Alison R., Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N., Casulo, Carla, Maloney, David G., de Vos, Sven, Reshef, Ran, Leslie, Lori A., Oluwole, Olalekan O., Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A. Scott, Miao, Harry, Beygi, Sara, Jacobson, Caron A.

“…•Axi-cel demonstrated durable responses in patients with FL and MZL after 3 years of follow-up.•Elevated baseline total metabolic tumor volume and recent prior…”
Get full text

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment by Gribben, John G., Bachy, Emmanuel, Ray, Markqayne, Krupsky, Kathryn, Beusterien, Kathleen, Kopenhafer, Lewis, Mendez, Flor, Beygi, Sara, Best, Timothy, Ball, Graeme, Perkowski, Kacper, Olsen, Patrick, Patel, Anik R, Ghione, Paola

“…Introduction: Follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma with limited treatment options at disease progression. Novel treatments,…”
Get full text

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma by Shree, Tanaya, Khodadoust, Michael S., Czerwinski, Debra K., Frank, Matthew J., Beygi, Sara, Long, Steven R., Martin, Brock, Levy, Ronald

“…Introduction: Local treatment with intratumoral CpG (a toll-like receptor 9 agonist, SD-101) and low-dose radiation can elicit antitumor immune responses and…”
Get full text

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL) by Jacobson, Caron Alyce, Hemmer, Michael T., Hu, Zhen-Huan, Frank, Matthew Joshua, Popplewell, Leslie, Ahmed, Nausheen, Lin, Yi, Best, Timothy, Beygi, Sara, Miao, Harry H., Fu, Christine, Sun, Fang, Xu, Hairong, Pasquini, Marcelo C.

“…7509 Background: Axicabtagene ciloleucel (axi-cel) is an autologous CAR T approved for adult patients (pts) with r/r FL after ≥ 2 lines of systemic therapy. In…”
Get full text

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) by Ghione, Paola, Palomba, Maria Lia, Ray, Markqayne D., Limbrick-Oldfield, Eve H., Owen, Jess, Kanters, Steve, Bobillo, Sabela, Ribeiro, Maria Teresa, Jacobson, Caron A., Neelapu, Sattva S., Ghesquieres, Herve, Nahas, Myrna, Beygi, Sara, Patel, Anik R., Gribben, John G.

Get full text

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data by Kambhampati, Swetha, Wang, Hai-Lin, Yan, Jiali, Herrera, Alex F., Frank, Matthew J., Popplewell, Leslie L., Ahmed, Nausheen, Lin, Yi, Locke, Frederick L., Ghione, Paola, Gribben, John G., Best, Timothy, Fu, Christine, Beygi, Sara, Ray, Markqayne D, Bian, John, Hu, Zhen-Huan, Sun, Fang, Pasquini, Marcelo, Jacobson, Caron A.

“…Background: Axicabtagene ciloleucel (axi-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, achieved an overall response rate (ORR) of 94% and…”
Get full text

Comparison of Systemic Mycophenolate Mofetil with Topical Clobetasol in Lichen Planopilaris: A Parallel-Group, Assessor- and Analyst-Blinded, Randomized Controlled Trial by Lajevardi, Vahide, Ghodsi, Seyedeh Zahra, Goodarzi, Azadeh, Hejazi, Pardis, Azizpour, Arghavan, Beygi, Sara

“…Introduction Lichen planopilaris (LPP) is the most common cause of inflammatory immune-mediated cicatricial alopecia. If not diagnosed and treated properly, it…”
Get full text